Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir/Asunaprevir/Beclabuvir FDC DDI Study
NCT02045966Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinite time. Started Feb 2014; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02045966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045966.